Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS

Background The association between anthropometric measures, including height and BMI, and cancer has been widely discussed, but their role glioma development and survival remains unclear due to conflicting evidence. We synthesized existing data on the relationship between these measures and both the incidence and survival outcomes of glioma patients. Methods Papers reporting relationship between anthropometric measures and the risk of glioma, both incidence and survival, were regarded as relevant. All relevant papers published until January 31, 2024, were selected from PubMed, EMBASE, and the Cochrane Library. Studies were evaluated according to the modified Newcastle Ottawa Scale. Results were reported following the PRISMA reporting guideline. Hazard ratios, relative risks, and 95% confidence intervals were pooled and synthesized. Findings Among 940 screened articles, 23 were included. Taller height was associated with increased glioma (HR per 10 cm, 1.19; CI, 1.16 to 1.23) and glioblastoma risk (HR per 10 cm, 1.25; CI, 1.18 to 1.31). Higher BMI correlated with an increased glioma risk, both in categorical (RR, 1.08; CI, 1.03 to 1.12) and continuous measures (HR per 5kg/m2, 1.01; CI, 1.00 to 1.03). Glioblastoma demonstrated a higher incidence (HR per 5kg/m2, 1.02; 95% CI 1.00 to 1.05) and improved survival (HR 0.75; 95% CI 0.59 to 0.96) with increasing BMI. Interpretation This study synthesizes current evidence to provide critical insights into the relationship between glioma and anthropometric measures. Gliomas were influenced by these measures in terms of incidence and survival. Further research is necessary to uncover the underlying mechanisms and develop preventative or therapeutic strategies.

show abstract

GBM tumors are heterogeneous in their fatty acid metabolism and modulating fatty acid metabolism sensitizes cancer cells derived from recurring GBM tumors to temozolomide

Parik

Fernández-García

Lodi

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Glioblastoma is a highly lethal grade of astrocytoma with very low median survival. Despite extensive efforts, there is still a lack of alternatives that might improve these prospects. We uncovered that the chemotherapeutic agent temozolomide impinges on fatty acid synthesis and desaturation in newly diagnosed glioblastoma. This response is, however, blunted in recurring glioblastoma from the same patient. Further, we describe that disrupting cellular fatty acid homeostasis in favor of accumulation of saturated fatty acids such as palmitate synergizes with temozolomide treatment. Pharmacological inhibition of SCD and/or FADS2 allows palmitate accumulation and thus greatly augments temozolomide efficacy. This effect was independent of common GBM prognostic factors and was effective against cancer cells from recurring glioblastoma. In summary, we provide evidence that intracellular accumulation of saturated fatty acids in conjunction with temozolomide based chemotherapy induces death in glioblastoma cells derived from patients.

show abstract

Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS

Cited by 3 publications

References 36 publications

Baseline single institutional retrospective review of body mass index (BMI) as a prognostic indicator in patients with newly diagnosed glioblastoma (GBM)

Baseline single institutional retrospective review of body mass index (BMI) as a prognostic indicator in patients with newly diagnosed glioblastoma (GBM)

Anthropometrics, Cancer Risks, and Survival Outcomes in Adult Patients with Glioma – A Systematic Review and Meta-analysis

GBM tumors are heterogeneous in their fatty acid metabolism and modulating fatty acid metabolism sensitizes cancer cells derived from recurring GBM tumors to temozolomide

Contact Info

Product

Resources

About